Skip to main content
S&P 5007,743.98+0.28%DOW52,475.10+0.19%NASDAQ26,549.85+0.27%BTC$81,099.00-0.02%ETH$2,353.96-0.04%GOLD$4,081.20+0.16%OIL$101.94+2.04%
Smart Investors Daily
SID Premium
IN

NASDAQ · INDV

Indivior PLC

Healthcare · Drug Manufacturers - Specialty & Generic

$34.72

Up+$0.05 (+0.14%)

Updated Oct 28, 2026, 8:45 PM

SID Score

4.7/10

Composite research score

Smart Money

58/100

Neutral

Market cap
4.47B
P/E ratio
26.96
Dividend yield
0.00%
52-week range
$27.68 – $42.81
Volume
2.41M
Avg. volume
2.19M

Price performance · INDV

INDV price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 27, 2026

INDV closed at $34.72 after 21 trading sessions, down 5.11% for the selected period.

Last close
$34.72
Period change
-5.11%
Period low
$32.45
Period high
$36.59
Daily close
View OHLC price history
INDV OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 27, 2026$34.68$34.82$33.9301$34.722.41M
Oct 26, 2026$34.47$34.65$33.99$34.56916.79K
Oct 23, 2026$35.345$35.345$34.10$34.471.48M
Oct 22, 2026$34.77$35.36$34.54$35.33871.7K
Oct 21, 2026$34.92$35.15$34.56$34.793.34M
Oct 20, 2026$34.02$35.12$33.80$34.771.93M
Oct 19, 2026$32.60$34.19$32.48$33.872.28M
Oct 16, 2026$33.47$33.835$32.31$32.454.29M
Oct 15, 2026$34.57$34.855$33.54$33.621.75M
Oct 14, 2026$35.11$36.30$33.99$34.162.78M
Oct 13, 2026$36.09$36.26$35.19$35.421.94M
Oct 12, 2026$36.00$36.32$35.37$36.067.47M
Oct 9, 2026$35.45$36.14$35.21$35.834.8M
Oct 8, 2026$35.725$36.35$34.85$35.451.53M
Oct 7, 2026$35.58$36.295$35.58$36.131.77M
Oct 6, 2026$35.96$36.1483$35.03$35.902.39M
Oct 5, 2026$36.00$36.2567$35.7301$35.993M
Oct 2, 2026$35.46$36.15$35.26$35.711.67M
Oct 1, 2026$35.85$36.205$35.25$35.381.88M
Sep 30, 2026$36.54$36.60$35.79$35.851.67M
Sep 29, 2026$36.74$37.05$36.08$36.592.01M

Latest INDV news

The latest Smart Investors Daily articles mentioning INDV.

Stock researchCompany · Overview

INDV research

Overview

Company profile and research snapshot.

Company profile

Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$38.00
Implied upside
—
Analysts
—
INDV recent ratings
DateFirmRatingTarget
Aug 5, 2026BarclaysOverweight—
Jun 18, 2026BarclaysOverweight—
Jan 12, 2026HC Wainwright & Co.Buy—
Oct 31, 2025Piper SandlerOverweight—
Oct 30, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 19, 2026

Indivior to Report Third Quarter 2026 Financial Results

RICHMOND, Va., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its third quarter 2026 financial results on Thursday, October 29, 2026. The results will be released at 7:00 a.m. U.S. EDT and will be available on the Company’s website at www.indivior.com. About Indivior As the leader in long-acting injectable treatments for opioid use disorder (OUD), Indivior is singularly focused on delivering evidence-based treatment and advanci

Yahoo · Sep 17, 2026

Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend

Payment of Special Dividend Contingent upon Closing of the Pending Merger TransactionRICHMOND, Va., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) (“Indivior”) today announced that its Board of Directors declared a special cash dividend (the "Special Dividend") in the amount of (i) $8.13 per share of Indivior common stock payable to holders of record of the issued and outstanding Indivior common stock as of October 30, 2026 (the “Special Dividend Record Date”) (

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By